Merck's Acquisition Plans#
Merck & Company is reportedly nearing a significant acquisition of Terns Pharmaceuticals for approximately $6 billion. This deal, expected to be finalized soon, will be an all-cash transaction that values Terns at a premium over its current market capitalization of around $5.3 billion.
Strengthening the Cancer Treatment Pipeline#
This acquisition is part of Merck's strategy to strengthen its portfolio of cancer treatments. The company is preparing for the potential loss of exclusivity for its leading cancer drug, Keytruda, which generates around $30 billion in annual revenue and may face competition starting in 2028.
Recent Acquisitions#
Merck has been active in the acquisition space recently, having purchased Verona Pharma for $10 billion and Cidara Therapeutics for $9.2 billion last year. These moves are aimed at countering anticipated revenue declines as patents expire on key products.
Terns Pharmaceuticals' Focus#
Terns Pharmaceuticals specializes in developing treatments for chronic myeloid leukaemia (CML), a rare cancer that affects blood and bone marrow. Their lead treatment could compete with Scemblix, a drug offered by competitor Novartis, highlighting the competitive landscape in cancer therapies.